Patients taking pentosan polysulfate sodium (PPS), which has been on the market for many years, appear to be at greater risk for a newly described maculopathy and vision loss, researchers report, according to Reuters.
“Exposure to PPS, the only FDA-approved oral medication for interstitial cystitis (IC), is strongly linked to a newly described, vision-threatening retinal condition. . . . It’s alarming that a drug that has been on the market for decades is now being implicated in a possible ocular toxicity,” cautioned senior author Dr. Nieraj Jain of Emory University School of Medicine in Atlanta, Georgia.
